Inovio expands manufacturing for COVID-19 vaccine

By The Science Advisory Board staff writers

May 1, 2020 -- Inovio has partnered with German contract manufacturer Richter-Helm BioLogics to produce large-scale quantities of Inovio's investigational DNA vaccine.

The INO-4800 vaccine is currently being tested in the U.S. through a phase I clinical trial. If proved safe, it could advance to phase II and III clinical trials later this year. Meanwhile, Richter-Helm BioLogics will transfer and rapidly scale up production processes for the INO-4800 DNA plasmid using its VGXI manufacturing technology.

The manufacturing partnership, which aims to produce 1 million doses of INO-4800 in 2020, is partly funded through a $1.3 million grant from the Coalition for Epidemic Preparedness Innovations (CEPI). Inovio also partners with Richter-Helm BioLogics for its DNA medicine candidate VGX-3100 for the potential treatment of HPV-related precancerous cervical dysplasia.

COVID-19: A double-edged sword for the pharma industry
The COVID-19 pandemic is causing major disruptions to pharmaceutical R&D activities, despite the pressing need for treatments and diagnostics for the...
CEPI, Clover to partner on COVID-19 vaccine
The Coalition for Epidemic Preparedness Innovations (CEPI) and Clover Biopharmaceuticals Australia plan to partner on the development of a COVID-19 vaccine.
COVID-19 vaccine candidates show progress amid challenges
As the COVID-19 outbreak advances worldwide, companies are stepping up to the challenge to develop a potential vaccine. There are over 75 confirmed COVID-19...
DOD grant accelerates SARS-CoV-2 vaccine manufacturing
The U.S. Department of Defense (DOD) has awarded Ology Bioservices and Inovio Pharmaceuticals an $11.9 million contract to rapidly manufacture DNA...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter